Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials

BACKGROUND: Preexisting drug resistance limits the utility of HIV antiretroviral therapy. Studies have demonstrated safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), including in patients with M184V/I substitutions. SETTING: We investigated virologic outcomes through...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Antoni, Michelle L., Andreatta, Kristen, Acosta, Rima, Martin, Hal, Chang, Silvia, Martin, Ross, White, Kirsten L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JAIDS Journal of Acquired Immune Deficiency Syndromes 2022
Materias:
Brief Report: Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860220/
https://www.ncbi.nlm.nih.gov/pubmed/34897227
http://dx.doi.org/10.1097/QAI.0000000000002888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860220/
https://www.ncbi.nlm.nih.gov/pubmed/34897227
http://dx.doi.org/10.1097/QAI.0000000000002888

Ejemplares similares